In line with an important role of EGFR and IL6 signaling in GLI-driven cancers, genetic and pharmacological inhibition of EGFR and IL6/JAK2/STAT3 signaling, respectively, interferes with GLI-driven tumor growth [116,117]. This evidence concerns the gene IL6 and neoplasm.